Prevention of osteoporosis: One step forward, two steps back

Menopause International

Volumn 17, Issue 4, 2011, Pages 137-141

  Stevenson, John C ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

bisphosphonates; HRT; Osteoporosis; other agents; safety

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ESTROGEN; GESTAGEN; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID;

BREAST CANCER; CANCER RECURRENCE; DIARRHEA; DRESS SYNDROME; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG POTENCY; DRUG SAFETY; ENDOCARDITIS; EOSINOPHILIA; ESOPHAGUS CANCER; EYE INFLAMMATION; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCORTISOLISM; JAW OSTEONECROSIS; NAUSEA; NONHUMAN; OSTEOPOROSIS; OSTEOSARCOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN INFECTION; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CALCIUM; DIPHOSPHONATES; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; NORPREGNENES; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINES AS TOPIC; TERIPARATIDE; THIOPHENES; VITAMIN D;

EID: 83055162206     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2011.011112     Document Type: Review

References (54)

1. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 221–32
2. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27
3. Stevenson JC on behalf of the International Consensus Group on HRT and Regulatory Issues. HRT, osteoporosis and regulatory authorities. Quis custodiet ipsos custodes? Hum Reprod 2006; 21: 1668–71
4. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701–12
5. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 2009; 207: 336–40
6. Rossouw JE, Prentice RL, Manson JE,, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465–77
7. Canonico M, Plu-Bureau G, Lowe GDO, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. Br Med J 2008; 336: 1227–31
8. Anderson GL, Chlebowski RT, Rossouw JE,, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006; 55: 103–15
9. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. HRT and breast cancer risk: a realistic perspective. Climacteric 2011; online 24 August
10. LaCroix A, Chlebowski RT, Manson JE,, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305: 1305–14
11. Shapiro S. Invited editorial. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric 2004; 7: 3–7
12. Black DM, Cummings SR, Karpf DB,, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–41
13. Harris ST, Watts NB, Genant HK,, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999; 344: 333–40
14. Miller PD, McClung MR, Macovei L,, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20: 1315–22
15. Eisman JA, Civitelli R, Adami S,, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA Study. J Rheumatol 2008; 35: 488–97
16. Black DM, Delmas PD, Eastell R,, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809–22
17. Cummings SR, Black DM, Thompson DE,, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1988; 280: 2077–82
18. Bhuriya R, Singh M, Molnar J, Arora R, Khosia S. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2010; 142: 213–217
19. Sharma NS, Masselos K, Hooper MJ, Francis IC. Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med 2008; 359: 1410–11
20. Bamias A, Kastritis E, Bamia C,, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580–7
21. Khan AA, Sandor GKB, Dore E,, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009; 36: 478–90
22. Goh S-K, Yang KY, Koh JSB,, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy. A caution. J Bone Joint Surg (Br) 2007; 89-B: 349–53
23. Park-Wyllie LY, Mamdani MM, Juurlink DN,, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783–789
24. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364: 1728–37
25. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach and colorectum: case-control analysis within a UK primary care cohort. Br Med J 2010; 341: c4444
26. Reid DM, Devogelaer J-P, Saag K,, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253–63
27. Watts NB, Diab DL. Long term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010; 95: 1555–65
28. Cummings SR, Ettinger B, Delmas PD,, et al. The effect of tibolone in older postmenopausal women. N Engl J Med 2008; 359: 697–708
29. Kenemans P, Bundred N, Foidart J-M,, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135–46
30. Miller PD, Chines AA, Christiansen C,, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-year results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008; 23: 525–35
31. Barrett-Connor E, Mosca L, Collins P,, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125–37
32. Silverman SL, Christiansen C, Genant HK,, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008; 23: 1923–34
33. Harvey JA, Holm MK, Ranganath R, Guse PA, Trott EA, Helzner E. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 2009; 16: 1193–6
34. Reginster J-Y, Felsenberg D, Boonen S,, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58: 1687–95
35. Servier Laboratories Limited. Summary of Product Characteristics – Protelos. Electronic Medicines Compendium (eMC), 2011; updated 31/08/2011
36. Neer RM, Arnaud CD, Zanchetta JR,, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434–40
37. Lasco A, Catalano A, Morabito N,, et al. Adrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosis. Osteoporosis Int 2011; 22: 299–303
38. Greenspan SL, Bone HG, Ettinger MP,, et al. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Int Med 2007; 146: 326–39
39. Ellerington MC, Hillard TC, Whitcroft SIJ,, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59: 6–11
40. Chesnut CH, Silverman S, Andriano K,, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000; 109: 267–76
41. Cummings SR, San Martin J, McClung MR,, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756–65
42. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 2010; 68: 959–64
43. Lacey DL, Timms E, Tan HL,, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–76
44. Anastasilakis AD, Toulis KA, Goulis DG,, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009; 41: 721–29
45. Chapuy MC, Arlot ME, Duboeuf F, Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637–42
46. Jackson RD, LaCroix AZ, Gass M,, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354: 669–83
47. Bolland MJ, Barber PA, Doughty RN,, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. Br Med J 2008; 336: 262–66
48. Bolland MJ, Avenell A, Baron JA,, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. Br Med J 2010; 341: c3691
49. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. Br Med J 2011; 342: d2040
50. Pickar JH, Mirkin S. Tisue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex. Menopause Int 2010; 16: 121–128
51. Shi X, Wang C, Zhuang Z,, et al. Nasal administration of a novel recombinant human parathyroid hormone (1-34) analog for the treatment of osteoporosis of ovariectomized rats. Regul Pept 2011; 170: 52–56
52. Bone HG, McClung MR, Roux C,, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010; 25: 937–47
53. Tian X-Y, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WSS. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone 2010; 47: 529–33
54. Agholme F, Isaksson H, Kuhstoss S, Aspenberg P. The effects of dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone 2011; 48: 988–96